Using PSA Doubling Time to Predict Metastatic Prostate Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time-the marker which currently provides the most information-and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time-the marker which currently provides the most information-and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Recent Videos
Findings from David Rimm, MD, PhD, suggest that there may be an inverse relationship between HER2 and TROP2 expression among patients with breast cancer.
Tissue samples collected from patients with breast cancer during treatment may help explore therapy selection and predict toxicities.
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Related Content
Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

SABCS 2025: The Top 5 Takeaways for Breast Cancer Research

Russ Conroy
December 18th 2025
Article

Sessions from SABCS 2025 detailed potential advances across different immunotherapy, radiation, and surgical modalities in breast cancer care.

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

CART19 Yields Promising Efficacy in CNS-Relapsed B-ALL

CART19 Yields Promising Efficacy in CNS-Relapsed B-ALL

Ariana Pelosci
December 16th 2025
Article

The 1-year EFS with CART19 was 90% among patients with B-ALL who had 1 or more CNS relapses.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.

Switching to Camizestrant Combo Improves PFS in HR+/HER2– Breast Cancer

Caroline Seymour
December 15th 2025
Article

Data from SERENA-6 showed delayed disease progression and deterioration in QOL among patients who switched to camizestrant plus CDK4/6 inhibition.

The BOOG 13-08 trial shows omitting sentinel lymph node biopsy is noninferior to performing it in select older patients with early-stage, HR+ breast cancer.

Omitting Sentinel Lymph Node Biopsy Is Safe in Select Patients With HR+ Early Breast Cancer

Gina Mauro
December 15th 2025
Article

The BOOG 13-08 trial shows omitting sentinel lymph node biopsy is noninferior to performing it in select older patients with early-stage, HR+ breast cancer.